Citation Impact
Citing Papers
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
2008
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Prevalence of pain in patients with breast cancer post-treatment: A systematic review
2018
Cancer treatment and survivorship statistics, 2022
2022 Standout
Breast cancer statistics, 2019
2019 Standout
Pathogenesis, clinical features, and treatment advances in mastocytosis
2006
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
2004
SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)
2005
Cremophor EL
2001 Standout
Ayurveda and Traditional Chinese Medicine: A Comparative Overview
2005 Standout
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
2006
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
2005
RB and cell cycle progression
2006 Standout
Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatment
2006
Rituximab therapy for childhood-onset systemic lupus erythematosus
2006
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma
2009
Systemic Lupus Erythematosus
2011 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case
2004
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study
2006
The Ki-67 protein: From the known and the unknown
2000 Standout
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Heavy Metal Content of Ayurvedic Herbal Medicine Products
2004
Diagnostic criteria and classification of mastocytosis: a consensus proposal
2001 Standout
The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases
1995
Clinical relevance of P-glycoprotein expression in haematological malignancies
1994
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
2003
Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids
2006
Heavy metals and living systems: An overview
2011 Standout
B-cell depletion in the treatment of mixed cryoglobulinemia
2007
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Bendamustine: Rebirth of an Old Drug
2009
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Cyclotides as grafting frameworks for protein engineering and drug design applications
2013
Retinoblastoma protein family in cell cycle and cancer: A review
1996
Computational Evolution of Threonine-Rich β-Hairpin Peptides Mimicking Specificity and Affinity of Antibodies
2019 StandoutNobel
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
2016
P-glycoprotein expression and function in circulating blood cells from normal volunteers
1994
Cancer treatment and survivorship statistics, 2019
2019 Standout
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20
2003
A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
1998 StandoutNobel
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
2008
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
2009
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
2018
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Works of Rudolf Weide being referenced
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors
2014
Altered expression of the human retinoblastoma gene in monocytic leukaemias
1993
Breast Cancer Morbidity
2014
Chronische Bleivergiftung durch ayurvedische Heilpillen
2003
Bendamustine Mitoxantrone and Rituximab (BMR): A New Effective Regimen for Refractory or Relapsed Indolent Lymphomas
2002
Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b
1996
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
2007
Bendamustine Plus Mitoxantrone—A New Effective Treatment for Advanced Chronic Lymphocytic Leukaemia: Results of a Phase I/II Study
2004
Induction of Complete Haematological Remission After Monotherapy with AntLCD20 Monoclonal Antibody (RITUXIMAB) in a Patient with Alkylating Agent Resistant Waldenstrom's Macroglobulinaemia
1999
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
2008
The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti‐CD20 monoclonal antibody rituximab
2000
The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
1990
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
2003
Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study
2004